Benefit of switching from a protease inhibitor (PI) to nevirapine in PI-experienced patients suffering acquired HIV-related lipodystrophy syndrome (AHL): interim analysis at 3 months of follow-up. (Q42662462)
Jump to navigation
Jump to search
scientific article published on January 1999
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Benefit of switching from a protease inhibitor (PI) to nevirapine in PI-experienced patients suffering acquired HIV-related lipodystrophy syndrome (AHL): interim analysis at 3 months of follow-up. |
scientific article published on January 1999 |
Statements
Benefit of switching from a protease inhibitor (PI) to nevirapine in PI-experienced patients suffering acquired HIV-related lipodystrophy syndrome (AHL): interim analysis at 3 months of follow-up (English)
Negredo E
Clotet B
Paredes R
Tuldrà A
Fumaz CR
Gel S
Garcés B
Johnston S
Arnó A
Balagué M
Jou A
Tural C
Sirera G
Romeu J
Cruz L
Francia E
Domingo P
Arrizabalaga J
Ruiz I